Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMW 2019 | Jorge Castillo: IMW 2019

Jorge Castillo • 13 Sep 2019
IMW 2019
Multiple Myeloma Rare Diseases Waldenström’s Macroglobulinemia

Jorge Castillo, MD Dana-Farber Cancer Institute, Boston, MA, reflects on the utility of the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Jorge Castillo

Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM 4:27
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM
Jorge Castillo • 8 Dec 2025
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM 2:54
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM
Jorge Castillo • 8 Dec 2025
Two-year follow-up after ibrutinib plus venetoclax in symptomatic treatment-naive WM 3:13
Two-year follow-up after ibrutinib plus venetoclax in symptomatic treatment-naive WM
Jorge Castillo • 7 Dec 2024
Interim analysis of a Phase II study of pirtobrutinib + venetoclax in previously treated WM 2:25
Interim analysis of a Phase II study of pirtobrutinib + venetoclax in previously treated WM
Jorge Castillo • 7 Dec 2024

Related Videos

RADAR trial: Isa-VRDc induction and Isa-VRD consolidation in newly diagnosed ultra-high-risk myeloma 1:23
RADAR trial: Isa-VRDc induction and Isa-VRD consolidation in newly diagnosed ultra-high-risk myeloma
Karthik Ramasamy • 7 Dec 2025
Initial results from MajesTEC-3: Tec-Dara versus DPd/DVd in patients with R/R multiple myeloma 3:53
Initial results from MajesTEC-3: Tec-Dara versus DPd/DVd in patients with R/R multiple myeloma
Luciano Costa • 16 Dec 2025
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals